518 related articles for article (PubMed ID: 32130964)
1. The Therapeutic Landscape of Renal Cell Carcinoma: From the Dark Age to the Golden Age.
Huang JJ; Hsieh JJ
Semin Nephrol; 2020 Jan; 40(1):28-41. PubMed ID: 32130964
[TBL] [Abstract][Full Text] [Related]
2. Circulating cytokines associated with clinical response to systemic therapy in metastatic renal cell carcinoma.
Chehrazi-Raffle A; Meza L; Alcantara M; Dizman N; Bergerot P; Salgia N; Hsu J; Ruel N; Salgia S; Malhotra J; Karczewska E; Kortylewski M; Pal S
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33688021
[TBL] [Abstract][Full Text] [Related]
3. Modern Systemic Therapy for Metastatic Renal Cell Carcinoma of the Clear Cell Type.
Parikh M; Lara PN
Annu Rev Med; 2018 Jan; 69():209-221. PubMed ID: 29144835
[TBL] [Abstract][Full Text] [Related]
4. Sequencing and Combination of Systemic Therapy in Metastatic Renal Cell Carcinoma.
de Velasco G; Bex A; Albiges L; Powles T; Rini BI; Motzer RJ; Heng DYC; Escudier B
Eur Urol Oncol; 2019 Sep; 2(5):505-514. PubMed ID: 31377308
[TBL] [Abstract][Full Text] [Related]
5. Biomarker-Oriented Therapy in Bladder and Renal Cancer.
Scholtes MP; Alberts AR; Iflé IG; Verhagen PCMS; van der Veldt AAM; Zuiverloon TCM
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33799514
[TBL] [Abstract][Full Text] [Related]
6. Complete response to immune checkpoint inhibitors-based therapy in advanced renal cell carcinoma patients. A meta-analysis of randomized clinical trials.
Iacovelli R; Ciccarese C; Schutz FA; Tortora G; de Velasco G
Urol Oncol; 2020 Oct; 38(10):798.e17-798.e24. PubMed ID: 32773231
[TBL] [Abstract][Full Text] [Related]
7. Significance of tumor microenvironment in acquiring resistance to vascular endothelial growth factor-tyrosine kinase inhibitor and recent advance of systemic treatment of clear cell renal cell carcinoma.
Mikami S; Mizuno R; Kosaka T; Tanaka N; Kuroda N; Nagashima Y; Okada Y; Oya M
Pathol Int; 2020 Oct; 70(10):712-723. PubMed ID: 32652869
[TBL] [Abstract][Full Text] [Related]
8. Effect of Antibiotic Use on Outcomes with Systemic Therapies in Metastatic Renal Cell Carcinoma.
Lalani AA; Xie W; Braun DA; Kaymakcalan M; Bossé D; Steinharter JA; Martini DJ; Simantov R; Lin X; Wei XX; McGregor BA; McKay RR; Harshman LC; Choueiri TK
Eur Urol Oncol; 2020 Jun; 3(3):372-381. PubMed ID: 31562048
[TBL] [Abstract][Full Text] [Related]
9. New therapeutic approaches in the management of metastatic renal cell carcinoma.
Gkialas IK; Papadopoulos G
J BUON; 2009; 14(3):399-404. PubMed ID: 19810129
[TBL] [Abstract][Full Text] [Related]
10. Evolving role of novel targeted agents in renal cell carcinoma.
Hutson TE; Figlin RA
Oncology (Williston Park); 2007 Sep; 21(10):1175-80; discussion 1184, 1187, 1190. PubMed ID: 17926797
[TBL] [Abstract][Full Text] [Related]
11. Reshaping Treatment Paradigms for Advanced Renal Cell Cancer Patients and Improving Patient Management : Optimal Management for Renal Cell Cancer Patients.
Cetin B; Wabl CA; Gumusay O
Curr Treat Options Oncol; 2022 Apr; 23(4):609-629. PubMed ID: 35316480
[TBL] [Abstract][Full Text] [Related]
12. Activity of cabozantinib after immune checkpoint blockade in metastatic clear-cell renal cell carcinoma.
McGregor BA; Lalani AA; Xie W; Steinharter JA; E Bakouny Z; Martini DJ; Fleischer JH; Abou-Alaiwi S; Nassar A; Nuzzo PV; Kaymakcalan MD; Braun DA; Wei XX; Harshman LC; Bilen MA; Choueiri TK
Eur J Cancer; 2020 Aug; 135():203-210. PubMed ID: 32599410
[TBL] [Abstract][Full Text] [Related]
13. Immune Checkpoint Inhibitors in the Treatment of Renal Cancer: Current State and Future Perspective.
Lavacchi D; Pellegrini E; Palmieri VE; Doni L; Mela MM; Di Maida F; Amedei A; Pillozzi S; Carini M; Antonuzzo L
Int J Mol Sci; 2020 Jun; 21(13):. PubMed ID: 32630154
[TBL] [Abstract][Full Text] [Related]
14. Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with second-line VEGFR-TKI after first-line immune checkpoint inhibitors.
Shah AY; Kotecha RR; Lemke EA; Chandramohan A; Chaim JL; Msaouel P; Xiao L; Gao J; Campbell MT; Zurita AJ; Wang J; Corn PG; Jonasch E; Motzer RJ; Sharma P; Voss MH; Tannir NM
Eur J Cancer; 2019 Jun; 114():67-75. PubMed ID: 31075726
[TBL] [Abstract][Full Text] [Related]
15. Signaling inhibitors in metastatic renal cell carcinoma.
Escudier B
Cancer J; 2008; 14(5):325-9. PubMed ID: 18836338
[TBL] [Abstract][Full Text] [Related]
16. Avelumab and axitinib combination therapy for the treatment of advanced renal cell carcinoma.
Soleimani M; Nappi L; Kollmannsberger C
Future Oncol; 2020 Dec; 16(36):3021-3034. PubMed ID: 32856478
[TBL] [Abstract][Full Text] [Related]
17. Checkpoint inhibitors in patients with metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Yip SM; Wells C; Moreira R; Wong A; Srinivas S; Beuselinck B; Porta C; Sim HW; Ernst DS; Rini BI; Yuasa T; Basappa NS; Kanesvaran R; Wood LA; Canil C; Kapoor A; Fu SYF; Choueiri TK; Heng DYC
Cancer; 2018 Sep; 124(18):3677-3683. PubMed ID: 30307610
[TBL] [Abstract][Full Text] [Related]
18. Tyrosine kinase and immune checkpoints inhibitors in favorable risk metastatic renal cell carcinoma: Trick or treat?
Catalano M; Procopio G; Sepe P; Santoni M; Sessa F; Villari D; Nesi G; Roviello G
Pharmacol Ther; 2023 Sep; 249():108499. PubMed ID: 37479037
[TBL] [Abstract][Full Text] [Related]
19. Immune checkpoint inhibitors in MITF family translocation renal cell carcinomas and genetic correlates of exceptional responders.
Boilève A; Carlo MI; Barthélémy P; Oudard S; Borchiellini D; Voss MH; George S; Chevreau C; Landman-Parker J; Tabone MD; Chism DD; Amin A; Bilen MA; Bosse D; Coulomb-L'hermine A; Su X; Choueiri TK; Tannir NM; Malouf GG
J Immunother Cancer; 2018 Dec; 6(1):159. PubMed ID: 30591082
[TBL] [Abstract][Full Text] [Related]
20. Immune checkpoint inhibition for the treatment of renal cell carcinoma.
Stühler V; Maas JM; Rausch S; Stenzl A; Bedke J
Expert Opin Biol Ther; 2020 Jan; 20(1):83-94. PubMed ID: 31587590
[No Abstract] [Full Text] [Related]
[Next] [New Search]
